TY - JOUR
T1 - Drug Repurposing Approaches towards Defeating Multidrug-Resistant Gram-Negative Pathogens
T2 - Novel Polymyxin/Non-Antibiotic Combinations
AU - Koh Jing Jie, Augustine
AU - Hussein, Maytham
AU - Rao, Gauri G.
AU - Li, Jian
AU - Velkov, Tony
N1 - Funding Information:
G.G.R., T.V., and J.L. are supported by the National Institute of Allergy and Infectious Diseases, award number R01AI146241. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Publisher Copyright:
© 2022 by the authors.
PY - 2022/12
Y1 - 2022/12
N2 - Multidrug-resistant (MDR) Gram-negative pathogens remain an unmet public health threat. In recent times, increased rates of resistance have been reported not only to commonly used antibiotics, but also to the last-resort antibiotics, such as polymyxins. More worryingly, despite the current trends in resistance, there is a lack of new antibiotics in the drug-discovery pipeline. Hence, it is imperative that new strategies are developed to preserve the clinical efficacy of the current antibiotics, particularly the last-line agents. Combining conventional antibiotics such as polymyxins with non-antibiotics (or adjuvants), has emerged as a novel and effective strategy against otherwise untreatable MDR pathogens. This review explores the available literature detailing the latest polymyxin/non-antibiotic combinations, their mechanisms of action, and potential avenues to advance their clinical application.
AB - Multidrug-resistant (MDR) Gram-negative pathogens remain an unmet public health threat. In recent times, increased rates of resistance have been reported not only to commonly used antibiotics, but also to the last-resort antibiotics, such as polymyxins. More worryingly, despite the current trends in resistance, there is a lack of new antibiotics in the drug-discovery pipeline. Hence, it is imperative that new strategies are developed to preserve the clinical efficacy of the current antibiotics, particularly the last-line agents. Combining conventional antibiotics such as polymyxins with non-antibiotics (or adjuvants), has emerged as a novel and effective strategy against otherwise untreatable MDR pathogens. This review explores the available literature detailing the latest polymyxin/non-antibiotic combinations, their mechanisms of action, and potential avenues to advance their clinical application.
KW - antimicrobial resistance
KW - drug repurposing
KW - non-antibiotic agents
KW - polymyxins
UR - https://www.scopus.com/pages/publications/85144716376
U2 - 10.3390/pathogens11121420
DO - 10.3390/pathogens11121420
M3 - Review Article
C2 - 36558754
AN - SCOPUS:85144716376
SN - 2076-0817
VL - 11
JO - Pathogens
JF - Pathogens
IS - 12
M1 - 1420
ER -